The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews.

@article{Monden2018TheCE,
  title={The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews.},
  author={Rei Monden and Annelieke M. Roest and Don van Ravenzwaaij and Eric-Jan Wagenmakers and Richard Donald Morey and Klaas J. Wardenaar and Peter de Jonge},
  journal={Journal of affective disorders},
  year={2018},
  volume={235},
  pages={
          393-398
        }
}

Figures and Tables from this paper

Comparing the Evidential Strength for Psychotropic Drugs: A Bayesian Meta-Analysis
TLDR
Although most psychotropic drugs were supported by strong evidence at the time of approval, some drugs only had moderate or even ambiguous evidence, showing the need for more systematic quantification and classification of statistical evidence for psychotrop drugs.
Comparing the evidential strength for psychotropic drugs: a Bayesian meta-analysis
TLDR
Although most drugs were supported by strong evidence at the time of approval, some only had moderate or ambiguous evidence, and results show the need for more systematic quantification and classification of statistical evidence for psychotropic drugs.
True and false positive rates for different criteria of evaluating statistical evidence from clinical trials
TLDR
Thinking about realistic effect sizes in conjunction with desirable levels of statistical evidence, as well as quantifying statistical evidence with Bayes factors may help improve decision-making in some circumstances.
Guidelines for the pharmacological acute treatment of major depression: conflicts with current evidence as demonstrated with the German S3-guidelines
TLDR
The recommendations in the S3-guidelines for the treatment of depression are in contradiction with the current evidence, and the risk-benefit ratio of AD for severe depression may be similar to the one estimated for mild depression and thus could be unfavorable.
Current Status of Vilazodone
TLDR
It can be concluded that more comparative research between vilazodone and other antidepressant is required in making better opinion about this drug.
Second-generation antidepressants for treatment of seasonal affective disorder.
TLDR
This update to assess the efficacy and safety of second-generation antidepressants (SGAs) for the treatment of seasonal affective disorder (SAD) in adults in comparison with placebo, light therapy, other SGAs, or psychotherapy is published.
Evaluating the evidential value of empirically supported psychological treatments (ESTs): A meta-scientific review.
TLDR
A metascientific review of the EST literature indicated that power and replicability estimates were concerningly low across almost all ESTs, and individually, some ESTs scored poorly across multiple metrics, with Strong ESTs failing to continuously outperform their Modest counterparts.
Bayes factors for superiority, non-inferiority, and equivalence designs
TLDR
Bayes factors for superiority, non-inferiority, and equivalence designs allow for explicit quantification of evidence in favor of the null hypothesis and allow for interim testing without the need to employ explicit corrections for multiple testing.
Expanding Statistical Frontiers in Sexual Science: Taxometric, Invariance, and Equivalence Testing
TLDR
This article discusses each of these analyses, providing conceptual and historical overviews, and describes current best practices when using each analysis, providing reproducible coding examples and interpretations along the way in an attempt to reduce barriers to the uptake ofThese analyses.
...
1
2
...

References

SHOWING 1-10 OF 63 REFERENCES
Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses.
TLDR
Examination of reporting biases in double-blind, placebo-controlled trials on the pharmacologic treatment of anxiety disorders found various reporting biases were present, and although these biases did not significantly inflate estimates of drug efficacy, reporting biases led to significant increases in the number of positive findings in the literature.
Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder
TLDR
A systematic review and meta-analysis of comparative evidence for 6 SSRIs and 4 other second-generation antidepressants is conducted, examining the role of these agents in the initial treatment of ambulatory adult patients with major depressive disorder.
Toward evidence‐based medical statistics: a Bayesian analysis of double‐blind placebo‐controlled antidepressant trials in the treatment of anxiety disorders
TLDR
The efficacy of FDA‐approved antidepressants for the treatment of anxiety disorders was re‐evaluated in a Bayesian framework that quantifies the strength of the evidence and indicates a varying strength of evidence between the trials with p < 0.05.
Frequency of Positive Studies Among Fixed and Flexible Dose Antidepressant Clinical Trials: An Analysis of the Food and Drug Administraton Summary Basis of Approval Reports
TLDR
It is suggested that the antidepressant dose schedule may influence trial outcome due in part to a significantly lower magnitude of symptom reduction with placebo in flexible dose trials (F=4.08, df=1, 48, p<0.05) compared to fixed dose trials.
Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
TLDR
Drug–placebo differences in antidepressant efficacy increase as a function of baseline severity, but are relatively small even for severely depressed patients.
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.
TLDR
Venlafaxine has greater efficacy than SSRIs although there is uncertainty in comparison with other antidepressants, and further studies are required to determine the clinical importance of this finding.
Efficacy and Acceptability of Pharmacological Treatments for Depressive Disorders in Primary Care: Systematic Review and Network Meta-Analysis
TLDR
Compared with other drugs, TCAs and SSRIs have the most solid evidence base for being effective in the primary care setting, but the effect size compared with placebo is relatively small.
Antidepressant drug effects and depression severity: a patient-level meta-analysis.
TLDR
The magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms.
Selective publication of antidepressant trials and its influence on apparent efficacy.
TLDR
A systematic literature search found that among 74 FDA-registered studies, 31%, accounting for 3449 study participants, were not published, and the increase in effect size ranged from 11 to 69% for individual drugs and was 32% overall.
...
1
2
3
4
5
...